Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Expectations By $0.06 EPS

Upstream Bio (NASDAQ:UPB) posted its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06), reports. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The company had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.52 million.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $9.79 on Friday. The stock has a 50-day simple moving average of $16.38 and a 200-day simple moving average of $21.42. Upstream Bio has a 52-week low of $5.14 and a 52-week high of $33.68. The firm has a market cap of $529.05 million, a price-to-earnings ratio of -5.21 and a beta of 2.96.

Analyst Ratings Changes

Several analysts recently commented on UPB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Lifesci Capital began coverage on Upstream Bio in a research report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price for the company. Finally, Mizuho upgraded Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Institutional Trading of Upstream Bio

Several large investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of Upstream Bio by 110.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,527 shares of the company’s stock worth $123,000 after acquiring an additional 3,430 shares in the last quarter. Bank of America Corp DE raised its position in shares of Upstream Bio by 71.2% in the 2nd quarter. Bank of America Corp DE now owns 18,031 shares of the company’s stock valued at $198,000 after acquiring an additional 7,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Upstream Bio by 85.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,084 shares of the company’s stock valued at $210,000 after acquiring an additional 8,788 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Upstream Bio during the second quarter worth $145,000. Finally, Invesco Ltd. raised its position in Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after buying an additional 985 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.